Kenneth LundstromPan Therapeutics
Dr. Lundstrom is a molecular biologist by training with unique combined experience in academia and the pharmaceutical/biotech industry. He is the author of more than 200 research articles, reviews and book chapters and a frequent invited speaker at international conferences. In parallel, he has long-term experience of large pharmaceutical organizations (Glaxo, Roche), medium-size companies (Cetus, Flamel Technologies) as well as start-ups (Regulon Inc., BioXtal). Dr. Lundstrom has a vast experience in project coordination by serving as the Scientific Coordinator of the privately funded structural genomics network MePNet (2001-04) and as a Steering Committee Member of the EU-funded E-MeP initiative. These activities involved close interaction with the pharmaceutical industry and fundraising activities. Dr. Lundstrom has lived in Switzerland since 1992 except for a short stay in UK in 1995-96. PanTherapeutics will profit from an experienced management team (see below) and due to the excellent scientific contacts from an attractive combination of strong academic research teams and a solid dedication to commercialization of research discoveries. PanTherapeutics has already initiated proof-of-concept studies. PanTherapeutics possesses an open-minded, innovative and pioneering approach.